Cellebrite names Shiven Ramji CEO, cuts 2026 revenue outlook - Investing.com

Cellebrite names Shiven Ramji CEO, cuts 2026 revenue outlook Company News Published 08/13/2026, 07:04 AM 0 © Reuters In this article: CLBT -4.87% TYSONS CORNER, Va. and PETAH TIKVA, Israel - Cellebrite DI Ltd. (NASDAQ:CLBT) announced today that Shiven Ramji has succeeded Thomas E. Hogan as chief executive officer, effective immediately. Ramji joined the company as President, Products and Technology in May 2026. The leadership change accompanies the company’s second-quarter 2026 results and a revised full-year outlook. Cellebrite lowered its fiscal 2026 annual recurring revenue guidance to $550 million to $560 million, representing 14% to 16% growth, down from previous expectations. The company also reduced its revenue outlook to $555 million to $561 million while raising its adjusted EBITDA target to $153 million to $159 million. For the second quarter ended June 30, 2026, Cellebrite reported revenue of $131.1 million, up 16% year-over-year. Annual recurring revenue reached $507.8 million, up 21% from the prior year. The company posted GAAP net income of $6.4 million and non-GAAP net income of $29.7 million. Adjusted EBITDA was $31.8 million with a margin of 24.2%. According to a company statement, ARR came in below expectations due to longer sales cycles and lower-than-anticipated expansion from Inseyets conversions. The company cited elongated sales cycles and delayed new product introductions as factors in its revised outlook. Hogan joined Cellebrite as Executive Chairman in August 2023, became interim CEO in January 2025, and was appointed CEO in August 2025. He will step down from the CEO role but his future involvement with the company was not specified in the statement. For the third quarter of 2026, Cellebrite expects ARR of $524 million to $528 million and revenue of $145 million to $148 million. The company projects adjusted EBITDA of $42 million to $45 million for the quarter. Cellebrite DI Follow Analyze CLBT Included in our AI-picked strategies · Review strategies 1D 1W 1M 6M 1Y 5Y Max Cellebrite provides digital investigative and intelligence solutions for law enforcement, defense, intelligence agencies and enterprises. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Is CLBT undervalued—or a trap? Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what CLBT is really worth. Get instant clarity on CLBT—plus thousands of other stocks—before the opportunity disappears. August Sale - 55% Off InvestingPro 0 Latest comments Post Comment Guidelines Indices Commodities Bonds Stocks 1D 1W 1M 6M 1Y 5Y Max US 30 53,928.20 +158.0 +0.29% US 500 7,761.30 +12.8 +0.16% Dow Jones 53,770.27 -21.58 -0.04% S&P 500 7,748.50 +20.30 +0.26% Nasdaq 26,588.49 +143.04 +0.54% S&P 500 VIX 14.57 +0.02 +0.14% Dollar Index 99.82 -0.079 -0.08% Most Popular Articles News Analysis These 2 AI stocks are "extremely undervalued", analyst says By Investing.co... Aug 13, 2026 Cisco’s AI-driven profit jump; PPI ahead - what’s moving markets By Investing.co... Aug 13, 2026 Stocks end largely higher as traders pare rate hike bets after July CPI report By Investing.co... Aug 12, 2026 KOSPI rebounds 20% from July low, set to exit bear market as chips rally By Investing.co... Aug 13, 2026 U.S. consumer price growth eases to 3.4% year-on-year in July By Investing.co... Aug 12, 2026 More News Market Movers Most Active Gainers % Losers % Name Last Chg. % Vol. MU 911.29 +4.92% 36.80M SPCX 146.15 +9.65% 167.24M NVDA 224.09 +3.03% 108.78M NBIS 259.20 +34.14% 63.54M INTC 100.95 +3.32% 162.45M SNDK 1,344.29 +5.76% 12.05M MSFT 492.43 -2.26% 29.00M Trending Stocks Name Last Chg. % Vol. NBIS 259.20 +34.14% 63.54M SPCX 146.15 +9.65% 167.24M MU 911.29 +4.92% 36.80M SMCI 37.61 +19.02% 165.74M NVDA 224.09 +3.03% 108.78M Show more Markets Ask WarrenAI Stocks Picked by AI Watchlist Alerts Top Brokers Breaking News Tools Install Our App Scan QR code to install app Follow us Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers. © 2007-2026 - Fusion Media Limited. All Rights Reserved.